Mark P. Smith

1.7k citations

48 papers · 1.2k indexed · h-index 23

Impact in

Hematology top 1%
- Hemophilia Treatment and Research
- Platelet Disorders and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Hemostasis and retained surgical items
Internal Medicine top 5%
- Venous Thromboembolism Diagnosis and Management

Papers in ⓘ

Hematology 36
- Hemophilia Treatment and Research 23
- Platelet Disorders and Treatments 16
- Blood Coagulation and Thrombosis Mechanisms 14
- Chronic Myeloid Leukemia Treatments 8
Internal Medicine 3
- Venous Thromboembolism Diagnosis and Management 3

Co-authors: Geoffrey F. Savidge (15 shared papers)Peter M. George (7 shared papers)Lucy Norris (2 shared papers)Gary Moore (4 shared papers)Philip Steer (2 shared papers)J. Bonnar (2 shared papers)Christopher A. Ludlam (2 shared papers)Elisabeth M. Cramer (2 shared papers)
Journals: Haemophilia (7 papers)Blood Coagulation & Fibrinolysis (5 papers)British Journal of Haematology (4 papers)Blood (3 papers)Thrombosis and Haemostasis (3 papers)
Partner nations: New Zealand United Kingdom United States

In The Last Decade

Mark P. Smith

48 papers receiving 1.2k citations

Peers

Countries citing papers authored by Mark P. Smith

Since Specialization

Citations

This map shows the geographic impact of Mark P. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark P. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark P. Smith more than expected).

Fields of papers citing papers by Mark P. Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark P. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark P. Smith. The network helps show where Mark P. Smith may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark P. Smith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark P. Smith Line = papers co-authored together Mark P. Smith links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 48 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	A mutation of human cytochrome c enhances the intrinsic apoptotic pathway but causes only thrombocytopenia Nature Genetics ·Ian M. Morison, Elisabeth M. Cramer, Emma J. Cheesman, Pak Leng Cheong, Andrew Holyoake, Serge Fichelson, Robert J. Weeks, Alexandra Lo, Stefan M.K. Davies, Sigurd M. Wilbanks, Robert D. Fagerlund, Mathew W. Ludgate, Fernanda M. da Silva Tatley, Melanie Sue Alanda Coker, Nicholas Bockett, Gillian Hughes, Diana A. Pippig, Mark P. Smith, Claude Capron, Elizabeth C. Ledgerwood	2008	129
2	Tinzaparin sodium for thrombosis treatment and prevention during pregnancy American Journal of Obstetrics and Gynecology ·Mark P. Smith, Lucy Norris, Philip Steer, Geoffrey F. Savidge, J. Bonnar	2004	71
3	Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII Haemophilia ·Michael Recht, László Nemes, Michał Matysiak, Marilyn J. Manco‐Johnson, Jeanne M. Lusher, Mark P. Smith, P.M. Mannucci, C. R. M. Hay, Thomas C. Abshire, Amanda C. O’Brien, Brooke Hayward, Chandrasekhar Udata, David A. Roth, Steven Arkin	2009	67
4	A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation British Journal of Haematology ·Christopher A. Ludlam, Mark P. Smith, Massimo Morfini, A. Gringeri, Elena Santagostino, Geoffrey F. Savidge	2003	65
5	Elective Surgery on Factor VIII Inhibitor Patients Using Continuous Infusion of Recombinant Activated Factor VII Thrombosis and Haemostasis ·Christopher A. Ludlam, Peter W. Collins, C. R. M. Hay, Jonathan T. Wilde, Alessandro Grigeri, Tina Melsen, Geoffrey F. Savidge, Mark P. Smith	2001	63
6	Phase I, Dose-Finding, and Pharmacokinetic Study of Raltitrexed Combined With Oxaliplatin in Patients With Advanced Cancer Journal of Clinical Oncology ·Karim Fizazi, Michel Ducreux, Pierre Ruffiè, M. Bonnay, Catherine Daniel, Jean‐Charles Soria, Catherine Hill, Abderrahim Fandi, Marc Poterre, Mark P. Smith, Jean‐Pierre Armand	2000	55
7	Immune Tolerance Therapy for Haemophilia A Patients with Acquired Factor VIII Alloantibodies: Comprehensive Analysis of Experience at a Single Institution Thrombosis and Haemostasis ·Katherine Spence, E. L. Waters, R. Beresford-Webb, Michael Mitchell, Jerry M. Cuttler, Anwar Alhaq, Simon Brown, Geoffrey F. Savidge, Mark P. Smith	1999	53
8	Double complex mutations involvingF8andFUNDC2caused by distinct break-induced replication Human Mutation ·Campbell R. Sheen, Ursula R. Jewell, Christine M. Morris, Stephen O. Brennan, Claude Férec, Peter M. George, Mark P. Smith, Jian‐Min Chen	2007	44
9	Immune Tolerance Therapy for Haemophilia Drugs ·Aloysius Ho, Susan E. Height, Mark P. Smith	2000	40
10	ReFacto®¹ and Advate®²: a single‐dose, randomized, two‐period crossover pharmacokinetics study in subjects with haemophilia A Haemophilia ·(unknown), Mark P. Smith, Robert Klamroth, P.M. Mannucci, Carl Kollmer, J. Feingold, C. M. Kessler, H. Pöllmann, Massimo Morfini, Chandrasekhar Udata, C. Rothschild, Cédric Hermans, Robert L. Janco	2007	39
11	The Ecarin time is an improved confirmatory test for the Taipan snake venom time in warfarinized patients with lupus anticoagulants Blood Coagulation & Fibrinolysis ·Gary Moore, Mark P. Smith, Geoffrey F. Savidge	2003	36
12	Detection of Factor VIII Gene Mutations by High-Resolution Melting Analysis Clinical Chemistry ·Andrew D. Laurie, Mark P. Smith, Peter M. George	2007	36
13	7 Megakaryocytes and platelets in α-granule disorders Baillière s Clinical Haematology ·Mark P. Smith, Elisabeth M. Cramer, Geoffrey F. Savidge	1997	35
14	Physician assessments of practice patterns in emergency department radiograph interpretation Annals of Emergency Medicine ·Margaret O'Leary, Mark P. Smith, William W. Olmsted, David J. Curtis	1988	35
15	Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy Thrombosis and Haemostasis ·J. Bonnar, Mark P. Smith, Philip Steer, Geoff Savidge, Lucy Norris	2004	34
16	Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE^® in patients with von Willebrand’s disease: a prospective multi‐centre study Haemophilia ·Scott Dunkley, Ross Baker, Michael Pidcock, Jamie Price, Michael Seldon, Mark P. Smith, Alison Street, Dermot Maher, Giulio Barrese, Christian D. Stone, J. V. Lloyd	2010	31
17	Variations in use of tertiary cardiac services in part of North-West England Health & Place ·Anthony C. Gatrell, Gillian Lancaster, Alison Chapple, Stephen Horsley, Mark P. Smith	2002	29
18	Heterozygous factor XI deficiency associated with three novel mutations British Journal of Haematology ·Michael Mitchell, Jacky Cutler, Simon R. Thompson, Gary Moore, E J ap Rees, Mark P. Smith, Geoffrey F. Savidge, Anwar Alhaq	1999	28
19	Preimplantation genetic diagnosis for hemophilia A using indirect linkage analysis and direct genotyping approaches Journal of Thrombosis and Haemostasis ·Andrew D. Laurie, A. M. Hill, James Harraway, Andrew Fellowes, G.T. PHILLIPSON, Peter S. Benny, Mark P. Smith, Peter M. George	2010	28
20	The identification and classification of 41 novel mutations in the factor VIII gene (F8C) Human Mutation ·Jacqueline A. Cutler, Mike Mitchell, Mark P. Smith, Geoffrey F. Savidge	2002	27

About Mark P. Smith

Mark P. Smith is a scholar working on Hematology, Internal Medicine, Genetics, Transplantation and Management of Technology and Innovation, having authored 48 papers that have together received 1.2k indexed citations. Recurring topics across this work include Hemophilia Treatment and Research (23 papers), Platelet Disorders and Treatments (16 papers), Blood Coagulation and Thrombosis Mechanisms (14 papers), Chronic Myeloid Leukemia Treatments (8 papers), Cancer-related gene regulation (6 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (4 papers), Venous Thromboembolism Diagnosis and Management (3 papers) and Blood properties and coagulation (3 papers). The work is most often cited by research in Hematology (822 citations), Internal Medicine (111 citations), Genetics (220 citations), Critical Care and Intensive Care Medicine (29 citations) and Cardiology and Cardiovascular Medicine (123 citations). Mark P. Smith has collaborated with scholars based in New Zealand, United Kingdom and United States. Frequent co-authors include Geoffrey F. Savidge, Peter M. George, Lucy Norris, Gary Moore, Philip Steer, J. Bonnar, Christopher A. Ludlam, Elisabeth M. Cramer, Andrew D. Laurie and Anwar Alhaq. Their work appears in journals such as Haemophilia, Blood Coagulation & Fibrinolysis, British Journal of Haematology, Blood and Thrombosis and Haemostasis.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact